Please login to the form below

Not currently logged in

Pfizer to close six research centres

Pfizer is to close six research and development facilities in the UK and US as part of its recent acquisition of Wyeth
Pfizer is to close six research and development facilities in the UK and US as part of its recent acquisition of Wyeth.

The remaining 14 out of the original 20 facilities will be consolidated into five main campuses and nine specialised units.

R&D operations will be eliminated in Gosport and Slough/Taplow in the UK; Princeton, New Jersey; Chazy, Rouses Point and Plattsburgh, New York; and Sanford and Research Triangle Park, North Carolina in the US.

Activities will also be significantly reduced at Collegeville, Pennsylvania; Pearl River, New York; and St Louis, Missouri. In addition, Pfizer will consolidate R&D functions from its New London, Connecticut site to its nearby research facility in Groton.

The restructuring will focus Pfizer's research activities on three main areas of biotherapeutics, pharmatherapeutics and vaccines, supported by specialised units such as monoclonal antibody discovery and regenerative medicine.

The five main research sites include Sandwich in Kent (UK); Cambridge, Massachusetts; Groton, Connecticut; Pearl River, New York; and La Jolla, California.

A broad outline of the restructure was announced back in April, when Wyeth stated that it expected a workforce reduction of 15 per cent – approximately 19,000 positions – as a result of the merger.

10th November 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....